A multi-institutional study led by researchers at UNC Lineberger Comprehensive Cancer Center, the Salk Institute for Biological Studies, and UC San Diego has uncovered new genetic rules that determine ...

The trial is conducted at the Mays Cancer Center, part of the University of Texas at San Antonio’s Health Science Center.

This image shows killer T cells surrounding and attacking a cancer cell. A new atlas developed by researchers at UC San Diego could make it possible to design custom T cells for immunotherapy to ...

CHAPEL HILL, N.C. - Feb. 4, 2026 - A multi-institutional study led by researchers at UNC Lineberger Comprehensive Cancer Center, the Salk Institute ...

First Phase 2 chemotherapy-free, lymphodepletion-free, off-the-shelf CAR-NK cell therapy plus ANKTIVA® and rituximab regimen ...

The market for TIGIT inhibitors is expected to grow significantly in the coming years. This is due to the increasing number ...

Flinders University researchers have discovered a rare genetic mutation that could explain why some people do not respond to ...

Global Cell Analyzer Market OverviewThe global cell analyzer market is poised for strong expansion, with forecasts indicating a CAGR of nearly 8% from 2025 to 2030. This growth trajectory is driven by ...

Early Phase 2a data suggest the IPF therapy GRI-0621 alters gene activity tied to inflammation, scarring, and tissue repair.

Dr. Maik Luu discusses how postbiotics can be used to reprogram CAR T cells to promote anti-tumor function and what further research is needed to bring probiotic-boosted therapies to the clinic.

A groundbreaking phase 2 trial explores a novel, chemotherapy-free immunotherapy for relapsed indolent B-cell lymphomas, aiming to enhance patient outcomes.